Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

Verdict

Headline takes no side. We score VNDA +1.00 — strongly bullish.

Headline says

No call

No rating or direction in the headline

Expected · VNDA

+1.00strongly bullish

−1 bearish0bullish +1

More positive than 99% of ticker scores this week